Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Colorcon
QuintilesIMS
Queensland Health
Fish and Richardson

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,980,853

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,980,853 protect, and when does it expire?

Patent 8,980,853 protects SPINRAZA and is included in one NDA.

This patent has forty patent family members in eighteen countries.

Summary for Patent: 8,980,853
Title:Compositions and methods for modulation of SMN2 splicing in a subject
Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s): Bennett; C. Frank (Carlsbad, CA), Hung; Gene (San Diego, CA), Rigo; Frank (Carlsbad, CA), Krainer; Adrian R. (Huntington Square, NY), Hua; Yimin (Jericho, NY), Passini; Marco A. (Shrewsbury, MA), Shihabuddin; Lamya (Brighton, MA), Cheng; Seng H. (Natick, MA), Klinger; Katherine W. (Sudbury, MA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA) Cold Spring Harbor Laboratory (Cold Spring Harbor, NY)
Application Number:13/380,021
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,980,853

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,980,853

PCT Information
PCT FiledJune 17, 2010PCT Application Number:PCT/US2010/039077
PCT Publication Date:December 23, 2010PCT Publication Number: WO2010/148249

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Julphar
Express Scripts
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.